CA-CITY-OF-HOPE
1.4.2021 16:02:12 CEST | Business Wire | Press release
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, today announced that it will extend its leading-edge cancer expertise to South America via an education agreement with Hospital Israelita Albert Einstein, a top cancer center in Latin America.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210401005185/en/
The three-year agreement calls for City of Hope to share its specialized cancer expertise with Hospital Israelita Albert Einstein’s oncology residents and clinical staff. City of Hope will provide educational experiences and host multidisciplinary tumor boards. Both institutions will explore potential innovative collaborations in precision oncology and research.
“This agreement marks another milestone moment, allowing City of Hope to extend its mission to eliminate cancer to a new continent,” said Harlan Levine , M.D., president of strategy and business ventures at City of Hope, which is headquartered near Los Angeles.
“Hospital Israelita Albert Einstein has an exceptional medical team,” Levine added. “City of Hope will offer our best-in-class expertise as a comprehensive cancer center to both their residents in training and clinical staff. We hope to collaborate with our Latin American colleagues to improve cancer care outcomes not only in São Paulo, but also throughout Brazil and Latin America.”
Among other services, City of Hope will provide a virtual multidisciplinary tumor board that will initially focus on gastrointestinal, genitourinary, lung and brain cancers. Hospital Israelita Albert Einstein physicians will share specific patient cases with complex issues involving molecular diagnostics, immunotherapy and innovations in cancer care delivery for review and discussion. City of Hope will also provide educational webinars and offer professional training on topics such as genetic testing, supportive care services and nursing.
Sidney Klajner, M.D., Ph.D., president of Hospital Israelita Albert Einstein, said, “We will incorporate City of Hope’s multidisciplinary approach to oncology precision medicine to address the cancer burden in Brazil. Together with City of Hope, we hope to collaborate on molecular diagnostics and innovative care advancements for the benefit of patients in Latin American and beyond.”
Hospital Israelita Albert Einstein has been ranked as the best hospital in Latin America by the America Economia Business Intelligence Unit for 12 years in a row. Additionally, it is positioned 36th overall globally and 21st for specialized oncology on Newsweek’s ranking of the World’s Best Hospitals 2021.
This collaborative agreement was made possible through efforts by City of Hope’s Center for International Medicine (CIM), which seeks to collaborate with international organizations to improve cancer and diabetes care for more people worldwide. CIM works with governments, hospitals, private companies and investors, and offers a range of services in the areas of clinical research and innovation, education and professional development.
About City of Hope
City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy . City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies, and numerous breakthrough cancer drugs are based on technology developed at the institution. Translational Genomics Research Institute (TGen) became a part of City of Hope in 2016. AccessHope TM , a wholly owned subsidiary, was launched in 2019, dedicated to serving employers and their health care partners by providing access to City of Hope’s exceptional cancer expertise. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona. For more information about City of Hope, follow us on Facebook , Twitter , YouTube or Instagram .
About Hospital Israelita Albert Einstein
Hospital Israelita Albert Einstein is a not-for-profit health care system based in São Paulo, Brazil. It encompasses activities in health care delivery, teaching, research, innovation and consultancy. In the private setting, the system manages a 600-bed general hospital and 10 satellite units spread around the greater metropolitan area of São Paulo and is dedicated to diagnostics and ambulatory medicine. In the public setting, the system manages two hospitals, with 600 beds in total and 24 ambulatory units. In 1999, the hospital became the first hospital outside of the U.S. to be accredited by Joint Commission International. It is currently the strategic partner of the Institute for Healthcare Improvement in Latin America.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005185/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom